Filing Details
- Accession Number:
- 0001209191-18-018707
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-12 08:49:56
- Reporting Period:
- 2018-03-08
- Accepted Time:
- 2018-03-12 08:49:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1178253 | Scynexis Inc | SCYX | Pharmaceutical Preparations (2834) | 562181648 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1656125 | Eric Francois | 101 Hudson Street Suite 3610 Jersey City NJ 07302-6548 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-03-08 | 5,917 | $1.69 | 24,917 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock Warrant (right to buy) | Acquisiton | 2018-03-08 | 4,437 | $0.00 | 4,437 | $1.85 |
Common Stock | Common Stock Warrant (right to buy) | Acquisiton | 2018-03-08 | 2,662 | $0.00 | 2,662 | $2.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,437 | 2018-03-08 | 2019-03-14 | No | 4 | P | Direct |
2,662 | 2018-03-08 | 2023-03-08 | No | 4 | P | Direct |
Footnotes
- Reflects the purchase on March 8, 2018, of 5,917 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant).